{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:01:10Z","timestamp":1751774470425,"version":"3.41.0"},"reference-count":29,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.5551\/jat.65186","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T22:13:34Z","timestamp":1737670414000},"page":"873-886","source":"Crossref","is-referenced-by-count":0,"title":["Secondary Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation and Advanced Chronic Kidney Disease"],"prefix":"10.5551","volume":"32","author":[{"given":"Yanzhao","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"},{"name":"Central Hospital of Dalian University of Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruopeng","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiwen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of Dalian Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol, 2013; 167: 1807-1824","DOI":"10.1016\/j.ijcard.2012.12.093"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol, 2001; 37: 371-378","DOI":"10.1016\/S0735-1097(00)01107-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology, 2013; 40: 227-239","DOI":"10.1159\/000343667"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146: 857-867","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Simic J, Mihajlovic M, Zec N, Kovacevic V, Marinkovic M, Mujovic N, Potpara T. The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease. Expert Rev Cardiovasc Ther, 2023; 21: 937-945","DOI":"10.1080\/14779072.2023.2270909"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol, 2019; 42: 774-782","DOI":"10.1002\/clc.23196"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Benn M. Atrial Fibrillation and Chronic Kidney Disease. Eur Heart J, 2021; 42: 2824-2826","DOI":"10.1093\/eurheartj\/ehab301"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Potpara TS, Ferro CJ, Lip G. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol, 2018; 14: 337-351","DOI":"10.1038\/nrneph.2018.19"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation, 2013; 127: 569-574","DOI":"10.1161\/CIRCULATIONAHA.112.123992"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol, 2013; 168: 4678-4684","DOI":"10.1016\/j.ijcard.2013.07.179"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol, 2013; 29: S71-S78","DOI":"10.1016\/j.cjca.2013.04.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant, 2012; 27: 3816-3822","DOI":"10.1093\/ndt\/gfs416"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol, 2014; 64: 2471-2482","DOI":"10.1016\/j.jacc.2014.09.051"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Arnao V, Agnelli G, Paciaroni M. Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. Intern Emerg Med, 2015; 10: 555-560","DOI":"10.1007\/s11739-015-1226-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Minematsu K, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke\/Transient Ischemic Attack. Cerebrovasc Dis, 2019; 48: 53-60","DOI":"10.1159\/000502883"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J, 2020; 223: 3-11","DOI":"10.1016\/j.ahj.2020.01.010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Welander F, Renlund H, Dimeny E, Holmberg H, Sjalander A. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. Clin Kidney J, 2023; 16: 835-844","DOI":"10.1093\/ckj\/sfad004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation, 2022; 146: 1735-1745","DOI":"10.1161\/CIRCULATIONAHA.121.054990"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, 2024; 105: S117-S314","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ding WY, Gupta D, Wong CF, Lip G. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res, 2021; 117: 1046-1059","DOI":"10.1093\/cvr\/cvaa258"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Christensen MA, Fosbol EL, Bonde AN, Olesen JB, Gislason GH, Torp-Pedersen C, Gundlund A. Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study. Europace, 2020; 22: 716-723","DOI":"10.1093\/europace\/euz340"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. J Am Heart Assoc, 2018; 7: e8928","DOI":"10.1161\/JAHA.118.008928"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Guo Z, Ding X, Ye Z, Chen W, Chen Y. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies. Clin Cardiol, 2021; 44: 917-924","DOI":"10.1002\/clc.23647"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006; 367: 1903-1912","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Chen JJ, Lin LY, Yang YH, Hwang JJ, Chen PC, Lin JL. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation--a nation-wide database analyses. Int J Cardiol, 2014; 177: 1008-1011","DOI":"10.1016\/j.ijcard.2014.09.140"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation, 2018; 138: 1519-1529","DOI":"10.1161\/CIRCULATIONAHA.118.035418"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Gerss J, Haeusler KG, Hewing B, Hoyer J, Juergensmeyer S, Klingenheben T, Knapp G, Christian RL, Schmidt-Guertler H, Wanner C, Kirchhof P, Goerlich D. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation, 2023; 147: 296-309","DOI":"10.1161\/CIRCULATIONAHA.122.062779"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Genovesi S, Rebora P, Gallieni M, Stella A, Badiali F, Conte F, Pasquali S, Bertoli S, Ondei P, Bonforte G, Pozzi C, Rossi E, Valsecchi MG, Santoro A. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. J Nephrol, 2017; 30: 573-581","DOI":"10.1007\/s40620-016-0364-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ballegaard E, Olesen JB, Kamper AL, Feldt-Rasmussen B, Gislason G, Torp-Pedersen C, Carlson N. Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease. Res Pract Thromb Haemost, 2024; 8: 102350","DOI":"10.1016\/j.rpth.2024.102350"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/7\/32_65186\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:45:29Z","timestamp":1751687129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/7\/32_65186\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65186","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"type":"print","value":"1340-3478"},{"type":"electronic","value":"1880-3873"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"65186"}}